Bristol-Myers, Merck making bids for share of hepatitis C market
This article was originally published in Scrip
Bristol-Myers Squibb and Merck & Co are emerging as formidable competitors in the race for better hepatitis C treatments, a trend that will be apparent at an upcoming medical conference.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.